This report presents findings related to the hepatitis B and C continuum of care, policy on testing and treatment, and the impact of the COVID-19 pandemic on hepatitis services in the EU/EEA from the second data collection conducted in 2021.
External quality assessment (EQA) is an essential part of any laboratory-based surveillance system, allowing for the monitoring of performance and comparability of results from participating laboratories, identification of potential issues and deployment of resources and training where necessary.
External quality assessment (EQA) is an essential part of any laboratory-based surveillance system, allowing for the monitoring of performance and comparability of results from participating laboratories, identification of potential issues and deployment of resources and training where necessary.
This report is the latest in a series published jointly by the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe that has been summarizing data on HIV and AIDS in the WHO European Region and in the European Union and European Economic Area (EU/EEA) since 2007.
The surveillance of Neisseria gonorrhoeae antimicrobial susceptibility in the European Union/European Economic Area (EU/EEA) is essential for detecting emerging and increasing antimicrobial resistance. Since 2009, this surveillance has been co-ordinated by the European Centre for Disease Prevention and Control (ECDC). The quality-assured data produced can be used to inform treatment guidelines.
In 2020, using data from countries able to provide at least two consecutive stages of the continuum, the overall performance of the European and Central Asian region against the global 90-90-90 targets is 82% of all PLHIV with HIV diagnosed, 67% of those diagnosed with HIV on treatment and 90% of those on treatment virally suppressed. More progress is needed to meet the substantive target of 73% of all PLHIV being virally suppressed, with performance for the overall region at 50% (based on the countries that submitted data for all four stages of the continuum).
For 2019, 30 EU/EEA Member States reported 29 996 cases of hepatitis B virus (HBV) infection. Excluding the five countries that only reported acute cases, the number of cases, 29 518, corresponds to a crude rate of 7.4 cases per 100 000 population.
In 2019, 37 733 cases of hepatitis C were reported in 29 EU/EEA Member States. Excluding countries that only reported acute cases leaves 37 660 cases, which corresponds to a crude rate of 8.9 cases per 100 000 population.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 18-24 July 2021 and includes updates on Escherichia coli ST38, COVID-19, Vibrio growth in the Baltic Sea the Olympic Games in Tokyo 2020 (2021), West Nile virus, avian influenza and cholera.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 4-10 July 2021 and includes updates on the Olympic games of Tokyo 2020, COVID-19, West Nile virus, measles, dengue, the UEFA European Football Championship 2020, and swine influenza.